Oxcarbazepine Suspension
Product Images NDC 70377-117

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 70377-117). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle-label.jpg (Bottle Label)

Label for Oxcarbazepine Oral Suspension, USP 300 mg/5 mL in a 250 mL bottle. The label includes dosage instructions to see the package insert, storage conditions between 20°C to 25°C with permitted excursions, and use within 7 weeks of opening. Manufactured for Biocon Pharma Inc., made by Carnegie Pharmaceuticals LLC.*

FDA Label Image

Carton (Carton)

The packaging label for Oxcarbazepine oral suspension, USP, 300 mg/5 mL strength in a 250 mL bottle. The label includes directions to shake well before use, storage instructions, and a note that each 5 mL contains 300 mg of oxcarbazepine. It lists Biocon Pharma Inc. as the labeler and Carnegie Pharmaceuticals LLC as the manufacturer. The NDC number 70377-117-11 is shown along with a barcode.*

FDA Label Image

Oxcarbazepine-fgure1 (Oxcarbazepine Fgure1)

A Kaplan-Meier survival curve plotting exit rate over time (days) from Day 2 to Day 11. The graph compares two treatment groups: Oxcarbazepine (solid line) and Placebo (dashed line), with a log-rank test p-value of 0.0001 indicated, showing differences in exit rates between groups.*

FDA Label Image

Oxcarbazepine-fgure10 (Oxcarbazepine Fgure10)

An instructional illustration showing hands removing the child-resistant cap from a bottle, relevant for oral suspension medications. The bottle has a safety cap being pressed and turned, demonstrating how to open it properly.*

FDA Label Image

Oxcarbazepine-fgure11 (Oxcarbazepine Fgure11)

An instructional illustration showing a hand holding a bottle and shaking it, indicating the need to shake the suspension before use.*

FDA Label Image

Oxcarbazepine-fgure12 (Oxcarbazepine Fgure12)

An instructional illustration demonstrating the proper method to use an oral syringe to withdraw OXCARBAZEPINE 60 mg/mL suspension from its bottle. The image shows a hand holding the bottle while another hand uses the syringe to extract the medication, with an arrow indicating the downward direction for syringe insertion.*

FDA Label Image

Oxcarbazepine-fgure13 (Oxcarbazepine Fgure13)

An instructional illustration showing how to measure liquid medication using a syringe. A bottle is inverted above the syringe, and the syringe is being pulled down to draw the liquid up from the bottle, with an arrow indicating the pulling motion. No specific product details are visible in the image.*

FDA Label Image

Oxcarbazepine-fgure14 (Oxcarbazepine Fgure14)

An instructional illustration showing how to measure and dose a liquid medication using an oral syringe. The image includes a close-up inset of the syringe's graduated markings indicating milliliter volumes for precise measurement.*

FDA Label Image

Oxcarbazepine-fgure15 (Oxcarbazepine Fgure15)

An instructional illustration showing a hand twisting or removing the cap from a bottle using a syringe inserted into the bottle neck, likely demonstrating how to extract or measure the oral suspension medication from the bottle.*

FDA Label Image

Oxcarbazepine-fgure16 (Oxcarbazepine Fgure16)

An instructional illustration showing the administration of Oxcarbazepine oral suspension. The image depicts a hand holding a syringe to measure the suspension, and a person using a syringe to take the oral dose. It demonstrates proper dosing technique for the 60 mg/mL oral suspension.*

FDA Label Image

Oxcarbazepine-fgure2 (Oxcarbazepine Fgure2)

A Kaplan-Meier survival curve chart showing seizure rates over time from first dose to first seizure. The chart compares data between two treatment groups: Oxcarbazepine and placebo, with days on the x-axis and seizure rate on the y-axis. A log-rank test with p-value of 0.046 is included.*

FDA Label Image

Oxcarbazepine-fgure3 (Oxcarbazepine Fgure3)

A Kaplan-Meier survival plot showing exit rate over time (days) for two treatment groups labeled HIGH and LOW. The chart compares the cumulative exit rate for both groups, with a log-rank test p-value of 0.0001 displayed on the graph.*

FDA Label Image

Oxcarbazepine-fgure4 (Oxcarbazepine Fgure4)

A Kaplan-Meier survival curve chart depicting the time to exit in days for two treatment groups labeled as HIGH and LOW. The solid line represents the HIGH treatment group, while the dashed line represents the LOW treatment group. The y-axis shows the exit rate ranging from 0.0 to 1.0. A log-rank test with a p-value of 0.0001 is indicated on the chart.*

FDA Label Image

Oxcarbazepine-fgure6 (Oxcarbazepine Fgure6)

The image shows a single-dose cup/package of OXCARBAZEPINE oral suspension. The cup appears cylindrical with a sealed top, typically used for unit-dose liquid medication dispensing.*

FDA Label Image

Oxcarbazepine-fgure7 (Oxcarbazepine Fgure7)

The image shows a gray bottle with a white screw cap containing an oral suspension. This product is Oxcarbazepine suspension, 60 mg/mL, manufactured by Biocon Pharma Inc. The bottle appears to be unlabelled aside from the cap.*

FDA Label Image

Oxcarbazepine-fgure8 (Oxcarbazepine Fgure8)

An instructional diagram of a syringe, labeled to identify the 'Barrel' and the 'Plunger' components. The syringe is depicted vertically with measurement markings on the barrel.*

FDA Label Image

Oxcarbazepine-fgure9 (Oxcarbazepine Fgure9)

An instructional illustration showing a hand holding and shaking a bottle, likely to indicate the proper method for mixing or preparing an oral suspension medication.*

FDA Label Image

Oxcarbazepine-structure (Oxcarbazepine Structure)

Chemical structure of oxcarbazepine, showing its molecular framework with fused rings and functional groups including ketone and amide moieties.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.